藥品研發受託製造廠商（CDMO）外包市場規模、佔有率和成長分析：按服務類型、應用和地區分類－2026-2033年產業預測

2024 年全球合約開發和受託製造廠商(CDMO) 外包市場價值為 2433.6 億美元，預計從 2025 年的 2589.4 億美元成長到 2033 年的 4253.3 億美元，在預測期（2026-2033 年）內以 6.4% 的複合年成長率成長。

全球合約研發受託製造廠商(CDMO) 外包市場凸顯了製藥業在藥物研發和生產方式上的重大轉變。透過與 CDMO 合作，製藥公司可以簡化流程，滿足日益成長的創新治療方法需求，同時避免建立大規模內部設施。 CDMO 目前提供全方位的服務，包括藥物研究、臨床前和臨床試驗支援、活性成分 (API) 生產以及劑型開發，涵蓋從研發到商業化的整個價值鏈。隨著製藥公司，尤其是中小企業，在藥物研發和生產方面面臨日益複雜的挑戰，對 CDMO 外包的需求預計將顯著成長，並重塑行業格局。

全球合約開發和受託製造廠商(CDMO) 外包市場的促進因素

全球合約研發受託製造廠商(CDMO) 外包市場正受到慢性病日益普遍的顯著推動。這主要是由於西式生活方式的傳播、經濟成長和人口成長所致。全球數百萬人口飽受慢性病困擾，推動了對醫療保健解決方案的需求。隨著慢性病日益普遍且需要持續管理，高效率的合約研發生產服務變得至關重要。這一趨勢凸顯了 CDMO 在支持製藥和生技產業滿足醫療保健需求方面發揮的關鍵作用。

全球合約開發和受託製造廠商（CDMO）外包市場的限制因素

預計多項挑戰將阻礙全球合約研發受託製造廠商（CDMO）外包市場的成長。嚴格的政府監管會顯著限制營運柔軟性，已開發國家各種小分子藥物和生物製藥的核准率下降也進一步加劇了市場格局的複雜性。此外，缺乏先進技術和設備的小規模CDMO常常面臨製程錯誤和品質波動等問題，導致成本增加和效率低。這些因素綜合起來，預計將在近期內構成阻礙，限制CDMO市場的整體擴張和發展。

全球合約開發與受託製造廠商（CDMO）外包市場趨勢

隨著製藥公司不斷尋求創新和高效的解決方案來簡化藥物研發流程，全球合約研發受託製造廠商（CDMO）外包市場正經歷著整合與合作方向的顯著轉變。這一趨勢的驅動力在於，生物製藥行業對滿足其多樣化需求的客製化服務的需求日益成長，CDMO 正在尋求與新興生物技術公司和成熟的製藥巨頭建立戰略合作夥伴關係。這些合作關係不僅拓展了服務範圍，還有助於快速創新和提供經濟高效的生產解決方案，使 CDMO 成為加速藥物研發生命週期、滿足生命科學領域不斷變化的需求的關鍵參與者。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球藥品研發受託製造廠商（CDMO）外包市場規模：依服務類型分類

• 合約開發
• 契約製造
• 綜合CDMO服務
• 其他

全球藥品開發與受託製造廠商(CDMO) 外包市場規模：依應用領域分類

• 腫瘤學
• 感染疾病
• 心血管疾病
• 神經病學
• 其他

全球藥品研發和受託製造廠商（CDMO）外包市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Lonza Group AG
• Catalent, Inc.
• Thermo Fisher Scientific Inc.
• WuXi AppTec Co., Ltd.
• Samsung Biologics Co., Ltd.
• Recipharm AB
• Boehringer Ingelheim International GmbH
• Fareva Group
• Siegfried Holding AG
• Almac Group Limited
• Evotec SE
• Cambrex Corporation
• Piramal Pharma Limited
• Jubilant Pharmova Limited
• Curia Global, Inc.
• PCI Pharma Services
• Vetter Pharma-Fertigung GmbH & Co. KG
• Aenova Group GmbH
• CordenPharma International GmbH
• Fujifilm Diosynth Biotechnologies

結論與建議

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market size was valued at USD 243.36 Billion in 2024 and is poised to grow from USD 258.94 Billion in 2025 to USD 425.33 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).

The market for global Contract Development and Manufacturing Organizations (CDMOs) highlights a pivotal shift in the pharmaceutical industry's approach to drug development and production. By collaborating with CDMOs, pharmaceutical companies can streamline the process, avoiding the need for extensive in-house facilities while responding to the growing demand for innovative therapies. CDMOs now offer a comprehensive suite of services that includes drug research, preclinical and clinical trial support, active pharmaceutical ingredient (API) production, and dosage form development, covering the entire value chain from research to commercialization. As pharmaceutical companies, particularly smaller firms, grapple with the increasing complexity of drug development and manufacturing challenges, the demand for CDMO outsourcing is expected to experience significant growth, shaping the future landscape of the industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contract Development And Manufacturing Organization (CDMO) Outsourcing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Segments Analysis

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market is segmented by Service Type, Application and region. Based on Service Type, the market is segmented into Contract Development, Contract Manufacturing, Integrated CDMO Services and Others. Based on Application, the market is segmented into Oncology, Infectious Diseases, Cardiovascular Diseases, Neurology and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market

The Global Contract Development and Manufacturing Organization (CDMO) Outsourcing market is significantly driven by the increasing prevalence of chronic diseases, which is largely influenced by the adoption of a westernized lifestyle, economic growth, and population growth. A substantial portion of the population grapples with chronic illnesses, with millions affected globally, leading to a greater demand for healthcare solutions. As chronic conditions become more common and often require ongoing management, the need for efficient contract development and manufacturing services becomes imperative. This trend underscores the critical role of CDMOs in supporting the pharmaceutical and biotechnology sectors in addressing healthcare demands.

Restraints in the Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market

Several challenges are poised to hinder the growth of the Global Contract Development and Manufacturing Organization (CDMO) outsourcing market. Stringent government regulations can significantly restrict operational flexibility, while a decrease in the approval rates for various small molecules and biologics in advanced economies further complicates the landscape. Moreover, smaller CDMOs that lack advanced technology and equipment often face issues related to process errors and inconsistent quality, leading to higher costs and inefficiencies. Collectively, these factors are expected to create barriers that may limit the overall expansion and development of the CDMO market in the foreseeable future.

Market Trends of the Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market

The Global Contract Development and Manufacturing Organization (CDMO) outsourcing market is experiencing a notable shift towards consolidation and collaboration as pharmaceutical companies increasingly seek innovative, efficient solutions to streamline drug development processes. This trend is driven by the rising demand for tailored services that cater to diverse biopharmaceutical needs, prompting CDMOs to form strategic partnerships with both emerging biotech firms and established pharmaceutical giants. These collaborations not only enhance service offerings but also facilitate rapid innovation and cost-effective manufacturing solutions, positioning CDMOs as pivotal players in accelerating the drug development lifecycle and meeting the evolving requirements of the life sciences sector.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Contract Development
• Contract Manufacturing
• Integrated CDMO Services
• Others

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Neurology
• Others

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size & CAGR (2026-2033)

• North America (Service Type, Application)
  • US
  • Canada
• Europe (Service Type, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service Type, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service Type, Application)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service Type, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fareva Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharmova Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PCI Pharma Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetter Pharma-Fertigung GmbH & Co. KG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aenova Group GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CordenPharma International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations